Table 3.
Summary of CTLA-4 and PD-1 expression in bronchoalveolar lavage fluid (BALF) CD4+ T cells.
| Diagnosis | CTLA-4+ | PD-1+ |
|---|---|---|
| Löfgren’s syndrome (LS) patient 1 | 1.55 | 19.10 |
| LS patient 2 | 1.69 | 34.20 |
| LS patient 3 | 2.45 | 51.50 |
| LS patient 4 | 1.88 | 21.30 |
| Median | 1.79* | 27.75# |
| Non-LS patient 1 | 1.43 | 15.00 |
| Non-LS patient 2 | 1.54 | 13.50 |
| Non-LS patient 3 | 1.29 | 14.20 |
| Non-LS patient 4 | 1.35 | 33.00 |
| Median | 1.39* | 14.60# |
| HC | 4.90 | 35.70 |
Percentages of CTLA-4+ and PD-1+, respectively, CD4+ T cells in BALF from individual LS and non-LS patients, as well as one healthy control (HC), as determined by manual gating of single, live (DNA+Cisplatin−), CD3+, CD4+, CD8− T cells in FlowJo X software. Comparison of median receptor expression in the respective patient groups by this method confirmed higher median expression of CTLA-4 (*p = 0.0286) and PD-1 (#p = 0.1143) in LS patients compared to non-LS (all comparisons by the non-parametric Mann–Whitney U test).